BIVI Stock — BioVie Inc.: Cash, EV, Pipeline

Share price

$1.61

Market cap

$13.6M

Cash

$9.0M

Enterprise value

$4.6M

Balance sheet

Cash	$9.0M
Debt	$0.0M
Net cash	$9.0M
Enterprise value	$4.6M
Basic shares	7.5M shares
Fully diluted shares	18.2M shares
Fully diluted market cap	$29.4M
Cash per share	$1.20

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading BIVI daily closes…

Loading price history…

Pipeline assets

Bezisterim

Phase 3 · Active Modality: oral small molecule

Aliases NE3107

Target ERK (ERK-binding; modulates NFκB/TNF inflammatory pathways)

Indications

Alzheimer's disease (Phase 3)
Parkinson's disease (Phase 2)
Long COVID (Phase 2)

Status note Phase 3 trial in mild to moderate probable AD (NCT04669028) topline announced Nov 29, 2023; securities class action re NM101 Phase 3/AD trial pending (class certification briefing due Jun 15, 2026). Phase 2b SUNRISE-PD topline announced; Phase 2 ADDRESS-LC in long COVID ongoing.

BIV201

Stage not disclosed · Active

Indications

Cirrhosis with ascites / refractory ascites (Stage not disclosed)

Status note Liver program. Finalizing Phase 3 protocol design for cirrhosis/ascites following FDA discussions in 2023 and 2025; no Phase 3 trial initiated per this filing.

Per-asset detail extracted from the 10-Q filed 2026-05-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	NE3107
Lead indication	Long COVID
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06847191	Phase 2	Active, not recruiting	Sponsor	BIVI	—	Long COVID	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for BioVie Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

BIVI — BioVie Inc.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials